

ICACT 2016

27th International Congress on Anti-Cancer Treatment

A world leading educational congress

2-4 February
2016

CENTRE DE CONFÉRENCE ÉTOILE SAINT-HONORÉ

21-23-25 rue Balzac - 75008 PARIS

Presidents

David Khayat, MD, PhD - Paris, France

Gabriel N. Hortobagyi, MD, PhD - Houston, USA

General Secretaries

Peter Harper, MD - London, UK


Moïse Namer, MD, PhD - Nice, France

Endorsed by



American Society of Clinical Oncology

This program has the American Society of Clinical Oncology's approval for quality of educational content. ASCO endorsement does not constitute medical advice. Health care providers should exercise their own independent medical judgment. ASCO® is a registered trademark of the American Society of Clinical Oncology®. Used with permission. This is not an ASCO sponsored event.



www.icact.com

ABSTRACT BOOK



**We strive to improve human health
and contribute to a society
enriched by smiles**



TAIHO PHARMACEUTICAL CO., LTD.

<http://www.taiho.co.jp/english/>

SPONSORS

27TH INTERNATIONAL CONGRESS ON ANTI-CANCER TREATMENT

With the support of:

MAJOR SPONSORS

- AMGEN

- ROCHE

SANOFI ONCOLOGY 

- SANOFI

SPONSORS

- FONDATION AVEC

- JANSSEN

- ONO

- TAIHO

- WISEPRESS



ICACT

**28TH INTERNATIONAL CONGRESS
ON ANTI-CANCER TREATMENT**

SAVE THE DATE

2017,

**31st January -2nd february
FRANCE**

**CENTRE DE CONFÉRENCE
ÉTOILE SAINT-HONORÉ
PARIS 8^e**

**More information on
the website soon!**

WWW.ICACT.COM

27TH INTERNATIONAL SCIENTIFIC COMMITTEE*

- ANDRÉ Fabrice
- ANDRÉ Thierry
- ANDRY Guy
- BASTIAN Gérard
- BAULIEUX Jacques
- BENJAMIN Robert S.
- BIZZARI Jean-Pierre
- BLAY Jean-Yves
- BONVALOT Sylvie
- BOYLE Peter
- BRASNU Daniel
- BUTHIAU Didier
- CASSOUX Nathalie
- CHAHINE Georges
- CHIRAS Jacques
- CLASSE Jean-Marc
- COHEN-ALORO Gilbert
- COINDRE Jean-Michel
- CONTE Pier-Franco
- CORTES Javier
- COSSET Jean-Marc
- CUSSENOT Olivier
- DALIVOUST Philippe
- DEBUS Juergen
- DE GRAMONT Aimery
- DELALOGUE Suzette
- DIAZ-RUBIO Eduardo
- DOUILLARD Jean-Yves
- DUCREUX Michel
- EGGERMONT Alexander
- EVENO Clarisse
- FIZAZI Karim
- FRYDMAN René
- FUMOLEAU Pierre
- GEORGOULIAS Vassilis
- GIANNI Luca
- GIL-DELGADO Marian
- GISSELBRECHT Christian
- GLEHEN Olivier
- GLIGOROV Joseph
- GOÉRÉ Diane
- Villejuif, France
- Paris, France
- Brussels, Belgium
- Paris, France
- Lyon, France
- Houston, USA
- New York, USA
- Lyon, France
- Paris, France
- Lyon, France
- Paris, France
- Paris, France
- Paris, France
- Beirut, Lebanon
- Paris, France
- Nantes, France
- Orange, France
- Bordeaux, France
- Padova, Italy
- Barcelona, Spain
- Paris, France
- Paris, France
- Marseille, France
- Heidelberg, Germany
- Paris, France
- Paris, France
- Madrid, Spain
- Nantes St Herblain, France
- Villejuif, France
- Villejuif, France
- Paris, France
- Villejuif, France
- Clamart, France
- Dijon, France
- Crete, Greece
- Milano, Italy
- Paris, France
- Paris, France
- Lyon, France
- Paris, France
- Villejuif, France

27TH INTERNATIONAL SCIENTIFIC COMMITTEE*

- GOODWIN Pamela Toronto, Canada
- GORNET Jean-Marc Paris, France
- GOUIN François Nantes, France
- GRUNENWALD Dominique Paris, France
- GUARNERI Valentina Padova, Italy
- HANNOUN Laurent Paris, France
- HARPER Peter London, UK
- HATAKE Kiyohiko Tokyo, Japan
- HERRERA Alain Paris, France
- HORTOBAGYI Gabriel Houston, USA
- HUDIS Clifford New-York, USA
- JUDET Henri Paris, France
- KAYITALIRE Louis New Jersey, USA
- KHAYAT David Paris, France
- KNOPF Alain Asnières, France
- LAUNOIS Bernard Paris, France
- LE CESNE Axel Villejuif, France
- LECOINTE Estelle Rennes, France
- LEFEBVRE Jean-Louis Lille, France
- LEJEUNE Ferdy Lausanne, Switzerland
- LICHINITSER Michael Moscow, Russia
- LINK Karl Heinrich Wiesbaden, Germany
- LO DICO Réa Paris, France
- LORIOT Yohann Villejuif, France
- LUCIDARME Olivier Paris, France
- MALOUF Gabriel Paris, France
- MANTION Georges Paris, France
- MARRE Philippe Paris, France
- MARTIN Miguel Madrid, Spain
- MAZERON JJacques Paris, France
- MEEUS Pierre Lyon, France
- MENEGAUX Fabrice Paris, France
- MEUNIER Bernard Rennes, France
- MILANO Gérard Nice, France
- MISSENARD Gilles Paris, France
- MORERE J.François Bobigny, France
- MORNEX Françoise Lyon, France
- MOTTET Nicolas Saint-Etienne, France*
- MULARONI Elena Cailungo, San Marino
- MULVEY Thérèse Boston, USA
- NAMER Moïse Nice, France

27TH INTERNATIONAL SCIENTIFIC COMMITTEE*

- PENAULT-LLORCA Frédérique
- PEREZ Edith
- PICCART Martine
- PIVOT Xavier
- POMEL Christophe
- PRITCHARD Kathleen I.
- RAY-COQUARD Isabelle
- ROSELL Rafael
- ROUGIER Philippe
- ROUZIER Roman
- SAIJO Nagahiro
- SALMON Rémy
- SCAGLIOTTI Georgio
- SHEPHERD Frances
- SCHNEIDER Maurice
- SOBRERO Alberto
- SORIA Jean-Charles
- SOTIRIOU Christos
- SPANO Jean-Philippe
- SPIELMANN Marc
- SUN Ying-Hao
- SWAIN Sandra
- TABERNERO Josep
- TAILLADE Laurent
- TOLEDANO Alain
- TOUBOUL Cyril
- TSUJI Yasushi
- UZAN Serge
- VAN CUTSEM Eric
- VAN GESTEL Dirk
- VAN POPPEL Henrik
- VERMORKEN Jan B.
- VILLENEUVE Laurent

Founding President :

- Pr Claude JACQUILLAT †

Honorary Presidents :

- Pr Pierre BANZET
- Pr James HOLLAND

Clermont-Ferrand, France
Jacksonville, USA
Brussels, Belgium
Besançon, France
Clermont-Ferrand, France
Toronto, Canada
Lyon, France
Baladona, Spain
Paris, France
Paris, France
Osaka, Japan
Paris, France
Turino, Italy
Toronto, Canada
Nice, France
Genoa, Italy
Villejuif, France
Brussels, Belgium
Paris, France
Villejuif, France
Shanghai, Chine
Washington, USA
Barcelona, Spain
Paris, France
Neuilly/Seine, France
Créteil, France
Sapporo, Japan
Paris, France
Leuven, Belgium
Brussels, Belgium
Leuven, Belgium
Edegem, Belgium

Paris, France

Paris, France

New York, USA

* Preliminary

ICACT 2016

27th International Congress on Anti-Cancer Treatment

A world leading educational congress



SKYTEAM®
GLOBAL MEETINGS

WITH SKYTEAM, YOUR GLOBAL MEETING IS SIMPLE TO ORGANISE AND EVEN EASIER TO GET TO.

Whether you are the organiser or the participant, the Global Meetings Program allows you to benefit from the expertise of SkyTeam's network covering over 1,000 destinations worldwide. Via the online portal, not only can participants obtain discounted travel, but flights and connections are made more convenient. Organisers can also take advantage of an online solution especially designed to meet their needs, including a productivity reward program. Additionally, we provide you with a communications kit and one point of contact to help manage your event. Visit our website www.skyteam.com/globalmeetings



AIR FARE DISCOUNT - Event ID : 3030S

SkyTeam Global Meetings Agreement - This Agreement is entered into by and among member airlines of the SkyTeam Alliance and EQUATOUR. The airlines of SKYTEAM, Official Alliance Network for 27th ICACT 2016, offer attractive airfares for participants. SKYTEAM comprises 19 leading international airlines serving 1000 destinations in 187 countries with over 15 000 flights daily.

GLOBAL MEETINGS PROGRAMME - TICKETS PURCHASING

The Discount Agreement will be for travel between January 28th through February 9th, 2016. To benefit from these special offers, link up with <http://globalmeetings.skyteam.com> and quote the Identifier Code 3030S. Tickets purchased on the following Carriers are eligible for the SkyTeam Global Meetings programme: Aeroflot, Aerolíneas Argentinas, Aeroméxico, Air Europa, Air France, Alitalia, China Airlines, China Eastern, China Southern, Czech Airlines, Delta Air Lines, Kenya Airways, KLM Royal Dutch Airlines, Korean Air, Middle East Airlines, Saudia, TAROM, Vietnam Airlines and Xiamen Air.

To book your travel now, visit www.skyteam.com/GlobalMeetings and enter your Event ID, **3030S**

Through this site you can also access the schedules of all SkyTeam partners to plan your flights on the airline of your choice.

5^{ÈME} COURS MULTIDISCIPLINAIRE SUR Le Cancer de la Prostate

NICE
SAINT PAUL
2016

SAVE THE DATE

15 AU 17 SEPTEMBRE
2016

COMITÉ SCIENTIFIQUE

Philippe BEUZÉBOC (Paris),
Patrick COLOBY (Pontoise),
Stéphane CULINE (Paris),
Jean-Louis DAVIN (Avignon),
Jean-Luc DESCOTES (Grenoble),
Jean-Michel HANOUN-LEVI (Nice),
Pierre RICHAUD (Bordeaux)

ORGANISÉ PAR :

Jean-Louis DAVIN (Avignon)
Moïse NAMER (Nice)



**PRÉ
PROGRAMME**

Valérie CAILLON
ORGANISATION LOGISTIQUE
valerie.caillon@im-events.com
Tél. 01 41 04 04 04

HÔTEL LE MÉRIDIDIEN
1, Promenade des Anglais - Nice - France

www.cours-rpc-nice-saintpaul.fr

AWARDS

24TH
CLAUDE JACQUILLAT
AWARD

F O R C L I N I C A L
C A N C E R R E S E A R C H

Eric Van Cutsem, MD, PhD

3rd SAVCHUK AWARD
IN ONCOLOGY CEREMONY

TBC

**SOMPS POSTER
AWARD**

AWARDS

Eric Van Cutsem, MD, PhD Paris 2016 University of Leuven

Eric Van Cutsem, MD, PhD, is since 2000 full professor at the University of Leuven (Belgium). He is responsible for the division of Digestive Oncology at the University Hospitals Gasthuisberg Leuven (UZLeuven) and University of Leuven (KUL) and is board member of Leuven Cancer Institute and of the Department of Oncology at the University of Leuven. He is member of Royal Academy of Medicine since 2015. Professor Van Cutsem obtained his medical degree in 1983 from the University of Leuven, specializing in internal medicine and he was awarded his PhD in 1994. He holds the special Chair of Digestive Oncology at the University of Leuven and has a mandate as clinical researcher of the Fund for Scientific Research (FWO). Throughout his training he has spent several months in England, Switzerland, the USA and the Netherlands and he has been involved in clinical and research projects.

Professor Van Cutsem has published more than 445 peer-reviewed articles and more than 905 articles in WEB OF SCIENCE, Thomson Reuters (H-factor: 90; > 37500 citations) and several chapters in books on gastrointestinal cancer. His work has been published in the most respected publications such as the New England Journal of Medicine, The Lancet, JAMA, Journal of Clinical Oncology, Nature Reviews Clinical Oncology, Annals of Oncology, European Journal of Cancer, British Journal of Cancer and Gastroenterology. He is coeditor of the reference text book on gastrointestinal cancer: Principles and Practice of Gastrointestinal Oncology: second edition, 2008. He was mentioned in 2013 in Capital (French magazine) amongst top 3 experts in the world on reputation in colon cancer and mentioned in Thomson Reuters within the 1 % highest impact in his domain (<http://highlycited.com/>).

He also co-ordinates several European and worldwide trials investigating new drugs for gastrointestinal cancer and serves on many Steering Committee and Advisory Boards. Eric Van Cutsem is a member of several scientific organizations including the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO), the American Association of Cancer Research (AACR), the European NeuroEndocrine Tumor Society (ENETS) and many national organizations. He was Member of the Programme Committee of ASCO 2003-2004, ASCO GI program committee 2004, 2006-2007 and is Member of the ASCO Cancer Education Committee 2005-2008.

Eric Van Cutsem is a member of several scientific organizations. He is/was a member of the Scientific Program Committee and/or educational committee of ASCO, ASCO-GI cancers symposium, ESMO, UEG and ECCO. He served for ESMO as executive board member 2011-

2013 and is since 2014 on the ESMO press committee. He was secretary from 2000 to 2003 and chair of the EORTC-GI group from 2003 to 2007 and is chairman of PETACC (Pan-

European Trials on Adjuvant Colon Cancer) since 2008; he is board member of the EORTC since 2009 and president of European Society of Digestive Oncology (ESDO) and is co-

chairman of the European Neuro-Endocrine Tumour Society (ENETS) registry. He was chairman of the governmental colon cancer prevention task force in Flanders, Belgium and is president of BGDO (Belgian Group Digestive Oncology), is president of FAPA (Familial Adenomatous Polyposis Association) and is executive board member of the Belgian Foundation Against Cancer. He is medical director of Europacol (patient advocacy group).

He has been the founder (1999) of and is chair of the Scientific Committee of the ESMO GI/ World Congress on Gastrointestinal Cancer in Barcelona (in partnership with ESMO since 2005).

2^{EME} CONGRÈS DE LA

Société Française de Médecine Prédicative et Personnalisée

9^{EMES} Universités des Thérapies Ciblées



SAVE
THE
DATE

PRE / PROGRAMME

Actualités et concepts émergents en médecine personnalisée

ADN circulant et séquençage très haut débit en pratique clinique

16 / PALAIS DES CONGRES DE MONTPELLIER (CORUM)
17 JUIN
2016

Comité d'organisation :

Pascal Pujol, David Azria, David Geneviève

Comité Scientifique :

Pierre Le Coz, Michael Grynberg, Frédérique Penault-Llorca, Arash Rafii,
Damien Sanlaville, Jean-Philippe Spano, Marc Spielmann, Daniel Zarca



www.sfmpp.fr

PROFFERED PAPERS

■ LUNG ■

POSTER

IC/AB2673

THE FREQUENCY OF METHODS USED FOR DETECTION OF THE EGFR MUTATION IN LUNG CANCER

JURISIC Vladimir
OBRADOVIC Jasmina

*University of Kragujevac, Serbia, Faculty of Medical Sciences, Kragujevac - Serbia
Faculty of Sciences, Kragujevac - Serbia*

Subject of study Epidermal growth factor receptor (EGFR) is a trans-membrane receptor protein and is over-expressed in several tumor types, including NSCLC. It was one of the molecules that were recognized as a potential biomarker for the development of targeted therapies. Many different methods were developed for detection commonly known mutations and for screening new mutations of the epidermal growth factor receptor in non-small cell lung cancer patients .

Methods

In our paper A Pub Med literature search was performed in order to demonstrate what methods are mostly used in detection of EGFR mutation in lung cancer, with aims to show their distribution through the last 10 years. In this search we took next key words: “mutations”, “epidermal growth factor receptor”, “EGFR”, “non-small cell lung cancer” or “NSCLC. We thus obtained 1,270 articles.

Results

Results shows that a lot of methods are used to determine mutations of EGFR in lung cancer. Immunohistochemical analysis (IHC), were not used only as single methods but very often in combination with direct sequencing (DS), and/or fluorescence in situ hybridization (FISH) and/or chromogenic in situ hybridization (CISH). IHC analyses in combination with PCR, direct sequencing, FISH or CISH were more frequently used in the period from 2001 to 2005. In the past six years direct sequencing, in combination with PCR alone or with PCR and other advanced techniques, has widely been used to detect EGFR mutation in NSCLC.

Conclusion

The certain methods are generally recommended to use in

the diagnosis of the tumor from biopsy. Other more sensitive methods are recommended to determine the presence of the mutation of EGFR from small tissue quantities.

POSTER

IC/AB2689

SUPPORT FOR PRIMARY LUNG CANCER. ABOUT 71 CASES TREATED AT THE ONCOLOGY RADIOTHERAPY DEPARTMENT OF ANTICANCER CENTER EMIR ABDELKADER, ORAN-ALGERIA

KHALDI Houria
LAHMER Kheira, DJEBBAR Amel, BOUKERCHE Abdelbaki

*Centre anticancer Emir Abdelkader, Radiothérapie Oncologie, Oran - Algérie
Service de Radiothérapie Oncologie-Centre Hospitalo-Universitaire, Oran - Algérie
Service de Radiothérapie Oncologie-Centre anticancer Emir Abdelkader, Oran - Algérie
Service de Radiothérapie Oncologie-Centre anticancer Emir Abdelkader, Oran - Algérie*

Introduction

The primary lung cancer is the leading cancer in men in western Algeria. In Oran, the primary lung cancer is the leading cancer in men and the tenth in women, with rates of 14.2% and 1.6% (cancer registry Oran).

Objectives

Study of epidemiological, clinical and therapeutic of primary lung cancer in western Algeria. Methodology Prospective study of 71 cases of primary lung cancer treated in 2014 in oncology radiotherapy department of Emir Abdelkader anticancer center.

Results

The average age is 61 years with a minimum 32 years and maximum 78 years. Patients from Oran represent 63% of cases, 12 patients had a family history of cancer, 34 showed a personal history of chronic disease or pulmonary disease and 66 patients are smoking. The predominant reason for consultation is coughing and chest pain. The average time between the first symptom is the consultation is 11 months. Sixty three patients were male and only eight are women. The stages II, III and IV respectively 66, 7%, 26%